Promising Target Antigens for Cell Therapy of Solid Tumors
Initially designed for hematological malignancies, CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens. Ongoing clinical trials are being conducted to evaluate the efficacy of CAR-T cells targeting FAP, GPC3, HER2, L1CAM, CEACAM5, MSLN, IL-13RA2, EpCAM, PSMA, and EGFR. Studies have demonstrated the ability of third-generation HER2 CAR-T cells to effectively eliminate glioblastoma cells, and their effectiveness can be further enhanced by combining them with PD-1 and CTLA-4 blockade. Cytokines such as IL4, TGF-β, IL-2, IL-7, IL-10, IL-12, and IL-15 are also known to play a significant role in the therapeutic effects of CAR-T therapy.
Sino Biological provides a comprehensive range of reagents and services to support the development of CAR-T therapies targeting solid tumors.